Also trades as: BIAFW (NASDAQ) · $vol 0M
BIAF NASDAQ
bioAffinity Technologies, Inc.
1W: -23.6%
1M: -37.9%
3M: -50.0%
YTD: -66.9%
1Y: -86.1%
3Y: -98.8%
$6.05
-0.09 (-1.46%)
Weekly Expected Move ±46.2%
$0
$3
$6
$9
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.5M
52W Range4.56-246.6
Volume154,233
Avg Volume2,075,727
Beta-1.11
Dividend—
Analyst Ratings
Company Info
CEOMaria Zannes
Employees57
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2022-09-01
Websitebioaffinitytech.com
3300 Nacogdoches Road
San Antonio, TX 78217
US
San Antonio, TX 78217
US
210 698 5334
About bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rios Roberto | 0 | — | 2025-08-12 | |
| Oppenheimer John J. | 0 | — | 2025-08-12 | |
| Reveles Xavier Trini | A-Award | 21,604 | — | 2025-01-10 |
| GIRGENTI STEVEN | A-Award | 14,814 | — | 2025-01-10 |
| Zannes Maria | A-Award | 37,037 | — | 2025-01-10 |